US urges tighter standards for HBV (Hepatitis B virus) screening
This article was originally published in Clinica
Executive Summary
An FDA advisory panel last week urged the agency to require more rigorous screening standards for the presence of the Hepatitis B virus (HBV) in US blood supplies. Voting unanimously, the panel recommended that the FDA alter its lot release specifications by lowering the limits of HBV detection that the lot must achieve.